Previous 10 | Next 10 |
LogicBio Therapeutics Announces Upcoming Presentations on GeneRide Development Candidate and Multiple Advancements in AAV Manufacturing Processes at ASGCT Annual Meeting PR Newswire - GeneRide ® LB-401 preclinical data in HT1 demonstrated substantial and d...
This week is another big week for the stock market, with CPI data coming on Wednesday. To identify peak inflation and a hopeful tipping point for the economy, traders await feverishly for some resolve. In the meantime, it doesn’t matter if you’re trading penny stocks o...
The shares of LogicBio Therapeutics (NASDAQ:LOGC) have jumped ~76% in the pre-market Monday after the gene editing firm announced that the U.S. Food and Drug Administration lifted its clinical hold on studies for the company’s lead asset LB-001. With the lifting of the clinic...
LogicBio Therapeutics Announces FDA Lifts Clinical Hold on SUNRISE Trial in Pediatric Patients with Methylmalonic Acidemia PR Newswire –Company initiates activities to resume dosing –Interim clinical data from Phase 1/2 trial expected to be presen...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s the beginning of the end as we break down all of the biggest pre-market stock movers for Friday! Source: Eric Urquhart/Shutterstock.com News out of China, earnings, FDA updates, and more have stocks on t...
LogicBio Therapeutics to Present at H.C. Wainwright Gene Therapy and Gene Editing Conference PR Newswire LEXINGTON, Mass. , March 23, 2022 /PRNewswire/ -- LogicBio ® Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine co...
LogicBio Therapeutics to Present at Barclays Global Healthcare Conference PR Newswire LEXINGTON, Mass. , March 8, 2022 /PRNewswire/ -- LogicBio ® Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that pres...
LogicBio press release (NASDAQ:LOGC): FY GAAP EPS of -$1.24 beats by $0.08. Revenue of $5.41M (+56.8% Y/Y) beats by $0.56M. For further details see: LogicBio GAAP EPS of -$1.24 beats by $0.08, revenue of $5.41M beats by $0.56M
LogicBio Therapeutics Reports Full Year 2021 Financial Results and Provides Business Updates PR Newswire LEXINGTON, Mass. , March 4, 2022 /PRNewswire/ -- LogicBio® Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company...
LogicBio Therapeutics (LOGC -2.5%) continues to trade lower as investors react to the FDA clinical hold imposed on its Phase 1/2 SUNRISE clinical trial for adeno-associated virus (AAV) genome editing therapy, LB-001, in children with methylmalonic acidemia (MMA). Noting the lack of clari...
News, Short Squeeze, Breakout and More Instantly...
LogicBio Therapeutics Inc. Company Name:
LOGC Stock Symbol:
NASDAQ Market:
LogicBio Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates PR Newswire - Pre-clinical results published in PLOS ONE demonstrating a single intravenous administration of mLB-001 in neonatal or adult MMA mice correlated with preventi...
NEW YORK, NY / ACCESSWIRE / October 20, 2022 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: KnowBe4, Inc. (NASDAQ:KNBE)'s s...
NEW YORK, NY / ACCESSWIRE / October 16, 2022 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: LogicBio Therapeutics, Inc. (NASD...